New and alternative approaches to tackling antibiotic resistance

F1000Prime Reports

Volumn 5, Issue , 2013, Pages

  Tillotson, Glenn S ^a   Theriault, Nicolette ^a  

^a TRANSCRIP PARTNERS LLP   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BRILACIDIN; CARBAPENEM DERIVATIVE; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; DAPTOMYCIN; FIMH INHIBITOR; GENTAMICIN; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; METAL OXIDE; NANOPARTICLE; PENICILLIN DERIVATIVE; PEPTIDOMIMETIC AGENT; PIPERACILLIN PLUS TAZOBACTAM; PLAZOMICIN; PNEUMOCOCCUS VACCINE; POL 7080; QUINOLONE DERIVATIVE; TETRACYCLINE DERIVATIVE; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL SKIN DISEASE; BACTERIOPHAGE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG WITHDRAWAL; ENTEROCOCCAL INFECTION; HUMAN; HYPERTENSION; LOW DRUG DOSE; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PARESTHESIA; QUORUM SENSING; SEPTICEMIA; SKIN TINGLING; STAPHYLOCOCCUS INFECTION; URINARY TRACT INFECTION;

EID: 84890255189     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P5-51     Document Type: Article

References (44)

1. Finland M, Kirby WM, Chabbert YA, Chain EB, Dowling HF, Garrod LP, Pettinga CW, Todd AC: Round table: are new antibiotics needed? Antimicrob Agents Chemother (Bethesda) 1965, 5:1107-14.
2. Livermore DM: Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med 2012, 27:128-42.
3. Rasheed JK, Kitchel B, Zhu W, Anderson KF, Clark NC, Ferraro MJ, Savard P, Humphries RM, Kallen AJ, Limbago BM: New Delhi metallo-β-lactamase- producing Enterobacteriaceae, United States. Emerging Infect Dis 2013, 19:870-8.
4. Tillotson GS, Draghi DC, Sahm DF, Tomfohrde KM, Del Fabro T, Critchley IA: Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study. J Antimicrob Chemother 2008, 62:109-15.
5. Marr AK, Gooderham WJ, Hancock RE: Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr Opin Pharmacol 2006, 6:468-72.
6. Hancock RE, Lehrer R: Cationic peptides: a new source of antibiotics. Trends Biotechnol 1998, 16:82-8.
7. Brogden KA: Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005, 3:238-50.
8. Shai Y: Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta 1999, 1462:55-70.
9. Huang Y, Huang J, Chen Y: Alpha-helical cationic antimicrobial peptides: relationships of structure and function. Protein Cell 2010, 1:143-52.
10. Peters BM, Shirtliff ME, Jabra-Rizk MA: Antimicrobial peptides: primeval molecules or future drugs? PLoS Pathog 2010, 6:e1001067.
11. McGrath DM, Barbu EM, Driessen WHP, Lasco TM, Tarrand JJ, Okhuysen PC, Kontoyiannis DP, Sidman RL, Pasqualini R, Arap W: Mechanism of action and initial evaluation of a membrane active all-D-enantiomer antimicrobial peptidomimetic. Proc Natl Acad Sci USA 2013, 110:3477-82.
12. Barbu EM, Shirazi F, McGrath DM, Albert N, Sidman RL, Pasqualini R, Arap W, Kontoyiannis DP: An antimicrobial peptidomimetic induces mucorales cell death through mitochondria-mediated apoptosis. PLoS ONE 2013, 8:e76981.
13. Brilacidin (PMX-30063) Antibiotic Fact Sheet. [http://files. shareholder.com/downloads/ABEA-4ITCYZ/1997024712x0x611205/ FEA66C67-D02F-4FF2- B230-AA711F46ED7F/PMX-30063-Antibiotic-Fact-Sheet-Nov-2012-.pdf]
14. Zaher HS, Green R: Fidelity at the molecular level: lessons from protein synthesis. Cell 2009, 136:746-62.
15. Ramirez MS, Tolmasky ME: Aminoglycoside modifying enzymes. Drug Resist Updat 2010, 13:151-71.
16. Ramirez MS, Nikolaidis N, Tolmasky ME: Rise and dissemination of aminoglycoside resistance: the aac(6′)-Ib paradigm. Front Microbiol 2013, 4:121.
17. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N: Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 2011, 66:48-53.
18. Galani I, Souli M, Daikos GL, Chrysouli Z, Poulakou G, Psichogiou M, Panagea T, Argyropoulou A, Stefanou I, Plakias G, Giamarellou H, Petrikkos G: Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J Chemother 2012, 24:191-4.
19. Cass RT, Brooks CD, Havrilla NA, Tack KJ, Borin MT, Young D, Bruss JB: Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects. Antimicrob Agents Chemother 2011, 55: 5874-80.
20. Griebling TL. Urinary tract infection in women. In: Litwin MS, Saigal CS, editors. Urologic Diseases in America. Washington, DC: U.S. Government Printing Office; 2007. pp. 587-620.
21. Gupta K, Hooton TM, Stamm WE: Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med 2001, 135:41-50.
22. Chen SL, Hung CS, Pinkner JS, Walker JN, Cusumano CK, Li Z, Bouckaert J, Gordon JI, Hultgren SJ: Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding. Proc Natl Acad Sci USA 2009, 106:22439-44.
23. Cusumano CK, Pinkner JS, Han Z, Greene SE, Ford BA, Crowley JR, Henderson JP, Janetka JW, Hultgren SJ: Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med 2011, 3:109ra115.
24. Han Z, Pinkner JS, Ford B, Chorell E, Crowley JM, Cusumano CK, Campbell S, Henderson JP, Hultgren SJ, Janetka JW: Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. J Med Chem 2012, 55:3945-59.
25. Tran N, Mir A, Mallik D, Sinha A, Nayar S, Webster TJ: Bactericidal effect of iron oxide nanoparticles on Staphylococcus aureus. Int J Nanomedicine 2010, 5:277-83.
26. Azam A, Ahmed AS, Oves M, Khan MS, Habib SS, Memic A: Antimicrobial activity of metal oxide nanoparticles against Gram-positive and Gram-negative bacteria: a comparative study. Int J Nanomedicine 2012, 7:6003-9.
27. Raghupathi KR, Koodali RT, Manna AC: Size-dependent bacterial growth inhibition and mechanism of antibacterial activity of zinc oxide nanoparticles. Langmuir 2011, 27:4020-8.
28. Xie Y, He Y, Irwin PL, Jin T, Shi X: Antibacterial activity and mechanism of action of zinc oxide nanoparticles against Campylobacter jejuni. Appl Environ Microbiol 2011, 77:2325-31.
29. Gajjar P, Pettee B, Britt DW, Huang W, Johnson WP, Anderson AJ: Antimicrobial activities of commercial nanoparticles against an environmental soil microbe, Pseudomonas putida KT2440. J Biol Eng 2009, 3:9.
30. Wang Z, Lee Y, Wu B, Horst A, Kang Y, Tang YJ, Chen D: Antimicrobial activities of aerosolized transition metal oxide nanoparticles. Chemosphere 2010, 80:525-9.
31. Baek Y, An Y: Microbial toxicity of metal oxide nanoparticles (CuO, NiO, ZnO, and Sb2O3) to Escherichia coli, Bacillus subtilis, and Streptococcus aureus. Sci Total Environ 2011, 409:1603-8.
32. Lin C, Fang Y, Al-Suwayeh SA, Yang S, Fang J: Percutaneous absorption and antibacterial activities of lipid nanocarriers loaded with dual drugs for acne treatment. Biol Pharm Bull 2013, 36:276-86.
33. Hazan R, He J, Xiao G, Dekimpe V, Apidianakis Y, Lesic B, Astrakas C, Déziel E, Lépine F, Rahme LG: Homeostatic interplay between bacterial cell-cell signaling and iron in virulence. PLoS Pathog 2010, 6:e1000810.
34. Ng W, Bassler BL: Bacterial quorum-sensing network architectures. Annu Rev Genet 2009, 43:197-222.
35. Que Y, Hazan R, Ryan CM, Milot S, Lépine F, Lydon M, Rahme LG: Production of Pseudomonas aeruginosa Intercellular Small Signaling Molecules in Human Burn Wounds. J Pathog 2011, 2011:549302.
36. Lesic B, Lépine F, Déziel E, Zhang J, Zhang Q, Padfield K, Castonguay M, Milot S, Stachel S, Tzika AA, Tompkins RG, Rahme LG: Inhibitors of pathogen intercellular signals as selective anti-infective compounds. PLoS Pathog 2007, 3:1229-39.
37. Shlaes DM: New β-lactam-β-lactamase inhibitor combinations in clinical development. Ann NY Acad Sci 2013, 1277: 105-14.
38. Levasseur P, Girard A, Claudon M, Goossens H, Black MT, Coleman K, Miossec C: In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2012, 56:1606-8.
39. Sabet M, Tarazi Z, Lomovskaya O, et al.: In Vivo Efficacy of the Beta-lactamase Inhibitor RPX 7009 combined with Biapenem (RPX 2003) Against KPC-producing K pneumoniae. [abstract].Presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2012; San Francisco, CA
40. Eravacycline:Eravacycline (TP-434). [http://tphase.com/pipeline/overview/ eravacycline/default.cfm.]
41. Lomovskaya O, Zgurskaya HI, Totrov M, Watkins WJ: Waltzing transporters and 'the dance macabre' between humans and bacteria. Nat Rev Drug Discov 2007, 6:56-65.
42. Machado D, Couto I, Perdigão J, Rodrigues L, Portugal I, Baptista P, Veigas B, Amaral L, Viveiros M: Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS ONE 2012, 7:e34538.
43. Zhang Q, Buckling A: Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms. Evol Appl 2012, 5:575-82.
44. Patel G, Bonomo RA: "Stormy waters ahead": global emergence of carbapenemases. Front Microbiol 2013, 4:48.